Market Overview:
The global mucormycosis market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of mucormycosis, rising awareness about the disease, and growing demand for effective diagnostic techniques. The market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into zygomycosis and rhinocerebral mucormycosis. Zygomycosis is further sub-segmented into pulmonary zygomycosis and disseminated zygomycoses. Rhinocerbal mucormycoisis is further sub-segmented into orbitoethmoidal infection, frontal sinusitis infection, nasopharyngeal infection, sphenoid sinusitis infection), and others). On the basis of application, hospitals & clinics accounted for majority share in 2017 owing to increasing number of hospital admissions due to fungal infections worldwide.
Product Definition:
Mucormycosis is a rare and life-threatening fungal infection that affects the sinuses, nose, or brain. Mucormycosis most often occurs in people with weakened immune systems. It can be deadly in up to 90% of cases. Treatment typically involves antibiotics and surgery.
Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027:
Global mucormycosis market was valued at USD 648.3 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.5% from 2021 to 2027. The increasing prevalence of mucormycosis, rising awareness among the population about the disease, technological advancements in diagnostics, and supportive government initiatives are some major factors driving the market for global mucormycosis over the forecast period.
Computed Tomography (CT):
Computed tomography (CT) scan is a diagnostic procedure that utilizes X-rays to produce 3D images of internal body structures. CT scans are most commonly used for scanning the head, chest, and abdominal areas. Mucormycosis is an infection caused by a fungus called aspergillus or mucormycosis which occurs in the lungs, air sacs, bronchioles & bronchitis and other parts of the respiratory tract.
Application Insights:
The global mucormycosis market is segmented on the basis of application into hospitals & clinics, medical institutes, research organizations and others. The hospitals & clinics segment dominated the overall market in terms of revenue share in 2027 owing to high incidence rates of Mucorales species infection and favorable reimbursement policies for treatment.
Medical institutes are anticipated to be the fastest-growing application sector over the forecast period due to increasing awareness about diagnosis and treatment methods as well as government initiatives that support these efforts. For instance, according to a study published by National Center for Biotechnology Information (NCBI) in 2018; around 10% - 15% of patients presenting with invasive pulmonary aspergillosis die despite aggressive therapy; therefore researchers from China studied 516 cases including both fatal and non-fatal invasive pulmonary aspergillosis between January 2014 - December 2017 across 26 provinces (China).
Regional Analysis:
North America dominated the global market in terms of revenue share in 2018. The presence of well-developed healthcare infrastructure and high awareness levels among individuals about the disease are some factors responsible for its large share. In addition, favorable reimbursement policies for diagnostic procedures also contribute to its large revenue share.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing cases of cancer and other infectious diseases due to rising population density, urbanization, and lack of proper hygiene & sanitation facilities in this region. Moreover, a rise in international travel will boost market growth further as it provides an opportunity for infection with Mucormycosis spore carriers from other countries thus contributing towards regional demand during the forecast period from 2019 to 2030 (Global mucormycosis Market by Region Forecast From 2018 To 2030).
Growth Factors:
- Increasing incidence of mucormycosis in immunocompromised patients
- Rising awareness about the disease and its diagnosis and treatment options
- Growing demand for novel antifungal drugs to treat mucormycosis
- increasing number of clinical trials for new antifungal agents for the treatment of mucormycosis
- expanding research on the pathogenesis and epidemiology of mucormycosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Mucormycosis Market Research Report
By Type
Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027, Computed Tomography (CT), Magnetic resonance imaging (MRI), Tissue Biopsy, Others
By Application
Hospitals & Clinics, Medical Institutes, Research Organization, Others
By Companies
Abbott Laboratories, Biocon, Cadila Pharmaceuticals, Novartis, Merck, Roche, Bristol Myers Squibb, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Mucormycosis Market Report Segments:
The global Mucormycosis market is segmented on the basis of:
Types
Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027, Computed Tomography (CT), Magnetic resonance imaging (MRI), Tissue Biopsy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals & Clinics, Medical Institutes, Research Organization, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Biocon
- Cadila Pharmaceuticals
- Novartis
- Merck
- Roche
- Bristol Myers Squibb
- Pfizer
Highlights of The Mucormycosis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027
- Computed Tomography (CT)
- Magnetic resonance imaging (MRI)
- Tissue Biopsy
- Others
- By Application:
- Hospitals & Clinics
- Medical Institutes
- Research Organization
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mucormycosis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mucormycosis is a fungal infection caused by the fungus Mucorales. The fungus grows in moist environments, such as the lungs, and can cause serious respiratory problems if not treated. Mucormycosis most commonly affects people who are smokers or have other lung diseases.
Some of the key players operating in the mucormycosis market are Abbott Laboratories, Biocon, Cadila Pharmaceuticals, Novartis, Merck, Roche, Bristol Myers Squibb, Pfizer.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mucormycosis Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Mucormycosis Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Mucormycosis Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Mucormycosis Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Mucormycosis Market Size & Forecast, 2018-2028 4.5.1 Mucormycosis Market Size and Y-o-Y Growth 4.5.2 Mucormycosis Market Absolute $ Opportunity
Chapter 5 Global Mucormycosis Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Mucormycosis Market Size Forecast by Type
5.2.1 Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027
5.2.2 Computed Tomography (CT)
5.2.3 Magnetic resonance imaging (MRI)
5.2.4 Tissue Biopsy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Mucormycosis Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Mucormycosis Market Size Forecast by Applications
6.2.1 Hospitals & Clinics
6.2.2 Medical Institutes
6.2.3 Research Organization
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mucormycosis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mucormycosis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Mucormycosis Analysis and Forecast
9.1 Introduction
9.2 North America Mucormycosis Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Mucormycosis Market Size Forecast by Type
9.6.1 Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027
9.6.2 Computed Tomography (CT)
9.6.3 Magnetic resonance imaging (MRI)
9.6.4 Tissue Biopsy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Mucormycosis Market Size Forecast by Applications
9.10.1 Hospitals & Clinics
9.10.2 Medical Institutes
9.10.3 Research Organization
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Mucormycosis Analysis and Forecast
10.1 Introduction
10.2 Europe Mucormycosis Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Mucormycosis Market Size Forecast by Type
10.6.1 Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027
10.6.2 Computed Tomography (CT)
10.6.3 Magnetic resonance imaging (MRI)
10.6.4 Tissue Biopsy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Mucormycosis Market Size Forecast by Applications
10.10.1 Hospitals & Clinics
10.10.2 Medical Institutes
10.10.3 Research Organization
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Mucormycosis Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Mucormycosis Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Mucormycosis Market Size Forecast by Type
11.6.1 Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027
11.6.2 Computed Tomography (CT)
11.6.3 Magnetic resonance imaging (MRI)
11.6.4 Tissue Biopsy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Mucormycosis Market Size Forecast by Applications
11.10.1 Hospitals & Clinics
11.10.2 Medical Institutes
11.10.3 Research Organization
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Mucormycosis Analysis and Forecast
12.1 Introduction
12.2 Latin America Mucormycosis Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Mucormycosis Market Size Forecast by Type
12.6.1 Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027
12.6.2 Computed Tomography (CT)
12.6.3 Magnetic resonance imaging (MRI)
12.6.4 Tissue Biopsy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Mucormycosis Market Size Forecast by Applications
12.10.1 Hospitals & Clinics
12.10.2 Medical Institutes
12.10.3 Research Organization
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Mucormycosis Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Mucormycosis Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Mucormycosis Market Size Forecast by Type
13.6.1 Global Mucormycosis Market Size Growth Rate by Diagnosis: 2016 VS 2021 VS 2027
13.6.2 Computed Tomography (CT)
13.6.3 Magnetic resonance imaging (MRI)
13.6.4 Tissue Biopsy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Mucormycosis Market Size Forecast by Applications
13.10.1 Hospitals & Clinics
13.10.2 Medical Institutes
13.10.3 Research Organization
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mucormycosis Market: Competitive Dashboard
14.2 Global Mucormycosis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Biocon
14.3.3 Cadila Pharmaceuticals
14.3.4 Novartis
14.3.5 Merck
14.3.6 Roche
14.3.7 Bristol Myers Squibb
14.3.8 Pfizer